A Phase 1 Study of SHR2554 in Subjects With Relapsed or Refractory Mature Lymphoid Neoplasms

NCT03603951 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

272

Enrollment

INDUSTRY

Sponsor class

Conditions

Relapsed or Refractory Mature Lymphoid Neoplasms

Interventions

DRUG: SHR2554

Sponsor

Jiangsu HengRui Medicine Co., Ltd.

Collaborators

[object Object]